Toyota|$17.84 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.99 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.57 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.95 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$513.68 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.89 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.40 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.31 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.47 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.64 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.40 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.64 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$465.98 (¥73,850)-2.29%▼ (in JPY terms)
Toyota|$17.84 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$24.99 (¥3,960)+0.03%▲ (in JPY terms)
SoftBank|$30.57 (¥4,845)-2.00%▼ (in JPY terms)
MUFG|$21.95 (¥3,478)+0.09%▲ (in JPY terms)
Keyence|$513.68 (¥81,410)+0.80%▲ (in JPY terms)
Nintendo|$53.89 (¥8,541)+0.73%▲ (in JPY terms)
NTT|$1.10 (¥175)+0.34%▲ (in JPY terms)
Takeda|$39.40 (¥6,244)+0.34%▲ (in JPY terms)
Tokyo Electron|$65.31 (¥10,350)-2.63%▼ (in JPY terms)
Recruit|$118.47 (¥18,775)+1.93%▲ (in JPY terms)
ITOCHU|$14.64 (¥2,320)+1.58%▲ (in JPY terms)
Honda|$11.40 (¥1,808)+0.56%▲ (in JPY terms)
Shin-Etsu|$37.64 (¥5,966)-0.20%▼ (in JPY terms)
Tokio Marine|$3.50 (¥555)-0.61%▼ (in JPY terms)
Fast Retailing|$465.98 (¥73,850)-2.29%▼ (in JPY terms)

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an additional indication for the antibody-drug conjugate Padsev™ (enfortumab vedotin) in combination with pembrolizumab for the treatment of muscle-invasive bladder cancer for which cisplatin is indicated.”

2026-05-14 Astellas Pharma Inc. “An application for approval in Japan has been submitted for an additional indication for the antibody-drug conjugate Padsev™ (enfortumab vedotin) in combination with pembrolizumab for the treatment of muscle-invasive bladder cancer for which cisplatin is indicated.”

コメントする